Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: The examining pagoclone for persistent developmental stuttering study

Journal of Clinical Psychopharmacology

Volumn 30, Issue 1, 2010, Pages 48-56

  Maguire, Gerald ^a   Franklin, David ^a   Vatakis, Nick G ^b   Morgenshtern, Elena ^b   Denko, Timothey ^c   Yaruss, J Scott ^d   Spotts, Crystal ^c   Davis, Larry ^e   Davis, Aaron ^e   Fox, Peter ^f   Soni, Poonam ^g   Blomgren, Michael ^g   Silverman, Andrew ^h   Riley, Glyndon ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Social Psychiatry Research Institute   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e Davis Clinic PC   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h NONE

Author keywords

Clinical trial; Pagoclone; Percent syllables stuttered; Stuttering

Indexed keywords

PAGOCLONE; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STUTTERING;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG PARTIAL AGONISM; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; NAPHTHYRIDINES; PILOT PROJECTS; RECEPTORS, GABA-A; STUTTERING; YOUNG ADULT;

EID: 74549123336     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181caebbe     Document Type: Article

References (41)

1. Bloodstein O. A Handbook on Stuttering. 5th ed. San Diego CA: Singular Publishing Group; 1995.
2. Teesson K, Packman A, Onslow M. The Lidcombe behavioral data language of stuttering. J Speech Lang Hear Res. 2003;46:1009-1015.
3. Conture EG. Stuttering: Its Nature, Diagnosis, and Treatment. Boston, MA: Allyn and Bacon; 2004.
4. Guitar B. Stuttering: An Integrated Approach to Its Nature and Treatment. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
5. Bennett EM. Working With People Who Stutter: A Lifespan Approach. Upper Saddle River, NJ: Pearson Merrill Prentice Hall; 2006.
6. Andrews G, Craig A, Feyer A, et al. Stuttering: a review of research findings and theories circa 1982. J Speech Hear Disord. 1983;48:226-263.
7. World Health Organization. The International Classification of Functioning, Disability, & Health. Geneva, Switzerland: World Health Organization; 2001.
8. Yaruss JS, Quesal RW. Stuttering and the International Classification of Functioning, Disability, and Health (ICF): an update. J Commun Disord. 2004;37:35-52.
9. Ingham JC, Riley G. Guidelines for documentation of treatment efficacy for young children who stutter. J Speech Lang Hear Res. 1998;41:753-770.
10. Maguire G, Yu B, Franklin D, et al. Alleviating stuttering with pharmacological interventions. Exp Opin Pharmacother. 2004;5: 1565-1571.
11. Fritzell B. The prognosis of stuttering school children: a 10-year longitudinal study. In: Proceedings of the XVI Congress of the International Society of Logopedics and Phoniatrics. Basel, Switzerland: Karger; 1976:186-187.
12. Howell P. Signs of developmental stuttering up to age eight and at 12 plus. Clin Psychol Rev. 2007;3:287-306.
13. Yairi E, Ambrose N. Early childhood stuttering I: persistence and recovery rates. J Speech Lang Hear Res. 1999;42:1098-1112.
14. Felsenfeld S, Kirk KM, Zhu G, et al. A study of the genetic and environmental etiology of stuttering in a selected twin sample. Behav Genet. 2000;30:359-366.
15. Howie PM. Concordance for stuttering in monozygotic and dyzygotic twin pairs. J Speech Hear Res. 1981;24:317-321.
16. Riaz N, Steinberg S, Ahmad J, et al. Genomewide significant linkage to stuttering on chromosome 12. Am Hum Genet. 2005;76: 647-651.
17. Suresh R, Ambros N, Roe C, et al. New complexities in the genetics of stuttering: significant sex-specific linkage signals. Am J Hum Genet. 2006;78:554-563.
18. Maguire G, Riley G, Yu B. A neurological basis of stuttering? Lancet Neurol. 2002;1:407.
19. Blomgren M, Nagarajan S, Lee J, et al. Preliminary results of a functional MRI study of brain activation patterns in stuttering and nonstuttering speakers during a lexical access task. J Fluency Disord. 2003;28:337-356.
20. Foundas AL, Bollich AM, Corey DM, et al. Anomalous anatomy of speech-language areas in adults with persistent developmental stuttering. Neurology. 2001;57:207-215.
21. Fox PT, Ingham RJ, Ingham JC, et al. A PET study of the neural systems of stuttering. Nature. 1996;382:158-162.
22. Neumann K, Euler H, von Gudenberg A, et al. The nature and treatment of stuttering as revealed by fMRI: a within-and between-group comparison. J Fluency Disord. 2003;28:381-410.
23. Wu JC, Maguire G, Riley G, et al. Increased dopamine activity associated with stuttering. Clin Neurosci Neuropsychol. 1997;8: 767-770.
24. Goberman A, Blomgren M. Parkinsonian speech disfluencies: effects of l-dopaYrelated fluctuations. J Fluency Disord. 2003;28:55-70.
25. Bothe AK, Davidow JH, Bramlett RE, et al. Stuttering treatment research, 1970-2005: I. Systematic review incorporating trial quality assessment of behavioral, cognitive, and related approaches. Am J Speech Lang Pathol. 2006;15:321-341.
26. Bothe AK, Davidow JH, Bramlett RE, et al. Stuttering treatment research, 1970-2005: II. Systematic review incorporating trial quality assessment of pharmacological approaches. Am J Speech Lang Pathol. 2006;15:342-352.
27. American Speech-Language-Hearing Association (ASHA). Guidelines for practice in stuttering treatment. Special Interest Division on Fluency and Fluency Disorders American Speech-Language-Hearing Association. ASHA Suppl. 1995;37(suppl 14):26-35.
28. Brady JP. The pharmacology of stuttering: a critical review. Am J Psychiatry. 1991;148:1309-1316.
29. Brady JP, Rynn M. Stuttering: current pharmacological options. CNS Drugs. 1994;1:163-168.
30. Maguire G, Riley G, Franklin B, et al. Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann Clin Psychiatry. 2004;16:63-67.
31. Farnbach-Pralong D, Bradbury R, Copolov B, et al. Clozapine and olanzapine treatment decreases rat cortical and limbic GABAA receptors. Eur J Pharmacol. 1998;349:R7-R8.
32. Sofuoglu M, Kosten T. Novel approaches to the treatment of cocaine addiction. CNS Drugs. 2005;19:13-25.
33. Riley G. Stuttering Severity Instrument 3rd Edition (SSI-3). Austin, TX: Pro-Ed; 1994.
34. Riley J, Riley G, Maguire G. Subjective screening of stuttering severity, locus of control and avoidance: research edition. J Fluency Disord. 2004;29:51-62.
35. Martin RR, Haroldson SK, Triden KA. Stuttering and speech naturalness. J Speech Hear Disord. 1984;49:53-58.
36. Blomgren M, Roy N, Callister T, et al. Intensive stuttering modification therapy: a multidimensional assessment of treatment outcomes. J Speech Lang Hear Res. 2005;48:509-523.
37. Andrews G, Ingham RJ. An approach to the evaluation of stuttering therapy. J Speech Hear Res. 1972;15:296-302.
38. Cordes AK, Ingham RJ. The reliability of observational data: II. Issues in the identification and measurement of stuttering events. J Speech Hear Res. 1994;37:279-294.
39. Ingham RJ. Stuttering and Behavior Therapy: Current Status and Empirical Foundations. San Diego, CA: College-Hill Press; 1984.
40. Ingham RJ, Costello JM. Stuttering treatment outcome evaluation. In: Costello JM, ed. Speech Disorders in Adults: Recent Advances. San Diego, CA: College-Hill; 1985:189-223.
41. Sawyer J, Yairi E. The effect of sample size on the assessment of stuttering severity. Am J Speech Lang Pathol. 2006;15:36-44.